Cas:40785-62-4 (4Z)-1,3,3a,6,7,8,9,10,11,12,13,13a-dodecahydrocyclododeca[c]furan manufacturer & supplier

Chemical Name:(4Z)-1,3,3a,6,7,8,9,10,11,12,13,13a-dodecahydrocyclododeca[c]furan

CAS.NO:40785-62-4

Synonyms:14-Oxabicyclo(10.3.0)pentadec-10-ene;14-Oxa-bicyclo(10.3.0)-2-pentadecene;3-Oxabicyclo(10.3.0)pentadecene-(6);EINECS 255-080-1;Muscogene;1,3,3a,4,5,6,7,8,9,10,11,13a-Dodecahydrocyclododeca(c)furan;Cyclododeca(c)furan,1,3,3a,4,5,6,7,8,9,10,11,13a-dodecahydro;3-Oxabicyclo<10.3.0>-6-pentadecen

Molecular Formula:C₁₄H₂₄O

Molecular Weight:208.34000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:303.9ºC at 760mmHg

Density:0.9g/cm3

Index of Refraction:1.463

PSA:9.23000

Exact Mass:208.18300

LogP:3.93960

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 14-Oxabicyclo(10.3.0)pentadec-10-ene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,-6-pentadecen physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,-6-pentadecen Use and application,3-Oxabicyclo(10.3.0)pentadecene-(6) technical grade,usp/ep/jp grade.

Related News: Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. (4Z)-1,3,3a,6,7,8,9,10,11,12,13,13a-dodecahydrocyclododeca[c]furan manufacturer Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. (4Z)-1,3,3a,6,7,8,9,10,11,12,13,13a-dodecahydrocyclododeca[c]furan supplier Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. (4Z)-1,3,3a,6,7,8,9,10,11,12,13,13a-dodecahydrocyclododeca[c]furan vendor Pharmaceutical intermediates and APIs belong to the fine chemical industry. (4Z)-1,3,3a,6,7,8,9,10,11,12,13,13a-dodecahydrocyclododeca[c]furan factory The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.